Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more ➡
Standard view
Full view
of .
Add note
Save to My Library
Sync to mobile
Look up keyword
Like this
0 of .
Results for:
No results containing your search query
P. 1


Ratings: (0)|Views: 298|Likes:
Published by Chris Nash

More info:

Published by: Chris Nash on Jul 26, 2008
Copyright:Attribution Non-commercial


Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See More
See less





 Effectiveness and Costs of OsteoporosisScreening and Hormone Replacement Therapy, Vol. I: Cost-Effectiveness Analysis
August 1995
OTA-BP-H-160GPO stock #052-003-01423-8
Recommended Citation:
U.S. Congress, Office of Technology Assessment,
Effectivenessand Costs of Osteoporosis Screening and Hormone Replacement Therapy,
Volume I:Cost-Effectiveness Analysis,
OTA-BP-H-160 (Washington, DC: U.S. GovernmentPrinting Office, August 1995).
enopause typically occurs in women around age 50. Accompany-ing this life event is a decline in estrogen levels and an increase inthe rate of decline in women’s bone density. This rapid bone lossincreases women’s subsequent risk of developing osteoporosis, adisease characterized by low bone density and increased bone fragility.Among the most serious consequences of osteoporosis is fracture of the hip,which may result in substantial morbidity, prolonged hospitalization, anddeath. Estrogen can prevent bone loss after menopause by replacing thebody’s own estrogen. Given the serious consequences of osteoporosis,some osteoporosis experts have recommended that women have their bonemineral density measured at the time of menopause and those with the low-est bone mineral density be offered
hormone replacement therapy,
com-prising estrogen given alone or in combination with the hormone progestin.This background paper,
Effectiveness and Costs of Osteoporosis Screen-ing and Hormone Replacement Therapy,
assesses the medical benefits andcosts of both screening and hormone replacement therapy. It is divided intotwo volumes. The first volume,
Cost-Effectiveness Analysis,
presents theresults of a model that estimates the cost per year of life gained from osteo-porosis screening and hormone replacement therapy in postmenopausalwomen. The second volume,
Evidence on Benefits, Risks, and Costs,
pro-vides the basis for the assumptions about the costs and effects of screeningand hormonal replacement therapy used in the cost-effectiveness model.This background paper is one of three documents resulting from OTA’sassessment of policy issues in the prevention and treatment of osteoporosis.This assessment was requested by the Senate Special Committee on Aging,Senator Charles Grassley and Senator John Glenn, and the House SelectCommittee on Aging, Representative Olympia J. Snowe, RepresentativeBenjamin A. Gilman, and former Representatives Brian J. Donnelly,Thomas J. Downey, and Patricia F. Saiki. Two background papers in this se-ries have been issued, both in July 1994:
Public Information about Osteopo-rosis: What’s’ Available, What’s Needed?,
 Hip Fracture Outcomes inPeople Age Fifty and Over 

You're Reading a Free Preview

/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->